Valeant Pharmaceuticals Intl (Put) (VRX) Shares Declined While Soros Fund Management LLC Decreased Stake

April 14, 2018 - By Eula Gilbert

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Corporate LogoBig Money Sentiment decreased to 0.97 in Q4 2017. It has change of 0.02, from 2017Q3’s 0.99. The ratio is negative due to VRX positioning: 51 sold and 74 reduced. 54 funds bought positions and 67 increased positions. Investors holded 169.87 million in 2017Q3 but now own 169.66 million shares or 0.12% less. Sivik Health Ltd Com holds 100,000 shs. Pinebridge Investments Limited Partnership holds 0% of its capital in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) for 3,854 shs. Ls Invest Advsr accumulated 140 shs. Jane Street Ltd stated it has 385,639 shs. Kemnay Advisory Svcs has invested 0.01% of its capital in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Cibc World invested in 0.32% or 3.42M shs. Advisory Networks Ltd Co holds 10,768 shs or 0.02% of its capital. Webster Financial Bank N A holds 0% or 300 shs in its capital. Andra Ap holds 0.06% or 98,800 shs in its capital. Tb Alternative Assets Limited holds 0.4% or 51,700 shs. Keybank Association Oh owns 10,000 shs. Brandywine Glob Inv Mngmt Lc has invested 0% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Citadel Limited Liability Corp invested 0% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Fincl Svcs has invested 0% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). 205 are owned by Fifth Third Financial Bank.

VRX had 0 sales and 3 insider purchases since March 8, 2018. This’s net activity of $876,370. On Tuesday, March 13 the insider Herendeen Paul bought $241,470. PAPA JOSEPH C also bought $481,500 worth of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) shs.

In Valeant Pharmaceuticals Intl (Put) (VRX) was decreased the holdings owned by George Soros. The reduction is 30.56% according to 2017Q4 SEC filling. The company’s stock sank 28.77% while Soros Fund Management Llc sold 660,000 shares. At the end of 2017Q4, the hedge fund run by George Soros held 1.50 million shares of the health care company, priced at $31.17 million, down from 2.16M at the end of the previous reported quarter. Valeant Pharmaceuticals Intl (Put) has $5.98 billion MC. On during the last trading session the stock increased $0.52 or 3.13%, reaching $17.15.Currently Valeant Pharmaceuticals International, Inc. is uptrending after 42.00% change in last April 14, 2017. VRX has 10.80 million shares volume. VRX outperformed by 30.45% the S&P500.

According to a filing the Soros Fund Management Llc’s stake in American Eagle Outfitters Ne (NYSE:AEO) was rose by 1.26 million shares to 1.28 million shares valued at $24.03 million in 2017Q4. It operates about $4.37 billion US Long portfolio. For a total of 199,000 shares it increased its holding in Aetna Inc New (NYSE:AET) by 110,900 shares in the quarter, and has risen its stake in Rockwell Collins Inc (NYSE:COL).

Analysts await Valeant Pharmaceuticals International, Inc. (NYSE:VRX) to report earnings on May, 8. They expect $0.66 EPS, down 76.43 % or $2.14 from last year’s $2.8 per share. VRX’s profit will be $230.25M for 6.50 P/E if the $0.66 EPS becomes a reality. After $0.98 actual EPS reported by Valeant Pharmaceuticals International, Inc. for the previous quarter, Wall Street now forecasts -32.65 % negative EPS growth.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Ratings Coverage

Total analysts of 15 have positions in Valeant Pharma (NYSE:VRX) as follows: 3 rated it a “Buy”, 4 with “Sell” and 8 with “Hold”. The positive are 20%. The firm has $25.0 highest while $7.0 is the lowest [Target]. The average target $16.27 is -5.13% below the last ($17.15) price. Since October 16, 2017 according to StockzIntelligence Inc Valeant Pharma has 30 analyst reports. On Monday, December 4 BTIG Research maintained Valeant Pharmaceuticals International, Inc. (NYSE:VRX) with “Hold” rating. The company rating was maintained by Canaccord Genuity on Monday, February 26. On Friday, October 20 the firm has “Sell” rating by Piper Jaffray given. On Wednesday, February 28 the stock of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has “Hold” rating given by CFRA. On Monday, March 5 the firm earned “Buy” rating by Deutsche Bank. On Friday, November 3 the rating was maintained by TD Securities with “Hold”. On Tuesday, November 7 the stock of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has “Buy” rating given by Cantor Fitzgerald. On Thursday, December 14 the stock has “Sell” rating by J.P. Morgan. On Friday, April 6 the rating was upgraded by Mizuho to “Hold”. On Friday, November 3 the company was maintained by H.C. Wainwright.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: